Agios Pharmaceuticals Inc.
Organization details
- Legal name
- Agios Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AGIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001439222
- Wikidata ID
- Q16824426
Board of directors
-
Brian Goff · Director · Chief Executive OfficerSince 2023
-
Catherine E. Owen · DirectorSince 2023
- Since 2023
-
David P. Schenkein · DirectorSince 2023
-
David Scadden · DirectorSince 2023
-
Jacqualyn A. Fouse · DirectorSince 2023
-
Jay T. Backstrom · DirectorSince 2025
-
Jeffrey D. Capello · DirectorSince 2023
- Since 2023
-
Kaye I. Foster-Cheek · DirectorSince 2023
-
Maykin Ho · DirectorSince 2023
-
Rahul D. Ballal · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
68.3%
-
87.1%
-
99.3%
Board connections
12 of this board's directors also sit on 26 other boards. 26 are in the same sector.
-
Prime Medicine Inc. Same sectorvia David P. Schenkein and Kaye I. Foster-Cheek
-
ACADIA Pharmaceuticals Inc. Same sectorvia Catherine E. Owen
-
Akebia Therapeutics Inc. Same sectorvia Cynthia Smith
-
Beam Therapeutics Inc. Same sectorvia John Maraganore
-
BioMarin Pharmaceutical Inc. Same sectorvia Maykin Ho
-
City Therapeutics Inc. Same sectorvia John Maraganore
-
Denali Therapeutics Inc. Same sectorvia David P. Schenkein
-
Disc Medicine Inc. Same sectorvia Jay T. Backstrom
-
Editas Medicine Inc. Same sectorvia David Scadden
-
Enliven Therapeutics Inc. Same sectorvia Rahul D. Ballal
-
Hemab Therapeutics Holdings Inc. Same sectorvia John Maraganore
-
Incyte Corp. Same sectorvia Jacqualyn A. Fouse
-
Intellia Therapeutics Inc. Same sectorvia Brian Goff
-
Kymera Therapeutics Inc. Same sectorvia John Maraganore
-
Kyntra Bio Inc. Same sectorvia Maykin Ho
-
Madrigal Pharmaceuticals Inc. Same sectorvia Jacqualyn A. Fouse
-
Neogen Corporation Same sectorvia Jeffrey D. Capello
-
Neumora Therapeutics Inc. Same sectorvia Maykin Ho
-
ProKidney Corp. Same sectorvia John Maraganore
-
Protara Therapeutics Inc. Same sectorvia Cynthia Smith
-
Rapport Therapeutics Inc. Same sectorvia John Maraganore
-
Regeneron Pharmaceuticals Inc. Same sectorvia David P. Schenkein
-
Scholar Rock Holding Corporation Same sectorvia Jay T. Backstrom
-
Spero Therapeutics Inc. Same sectorvia Cynthia Smith
-
Takeda Pharmaceutical Company Limited Same sectorvia John Maraganore
-
Tvardi Therapeutics Inc. Same sectorvia Cynthia Smith
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $4,868,645
- 41 sales by 8 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 26, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Option exercise | +7,866 | $25.01 | $196,729 |
| Oct 26, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Open-market sale | −7,866 | $37.69 | $296,470 |
| Oct 22, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Option exercise | +500 | $25.01 | $12,505 |
| Oct 22, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Open-market sale | −500 | $37.52 | $18,760 |
| Oct 21, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Option exercise | +1,489 | $25.01 | $37,240 |
| Oct 21, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Open-market sale | −1,489 | $37.53 | $55,882 |
| Aug 4, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Open-market sale | −30,000 | $30.48 | $914,400 |
| Jul 8, 2026 | Jay T. Backstrom Director | Grant or award | +1,447 | — | — |
| Jul 1, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Option exercise | +8,375 | — | — |
| Jul 1, 2026 | Sarah Gheuens Officer (Chief Medical Officer) | Open-market sale | −4,007 | $37.56 | $150,503 |
| Jun 18, 2026 | Rahul D. Ballal Director | Option exercise | +2,816 | — | — |
| Jun 18, 2026 | Jeffrey D. Capello Director | Option exercise | +2,816 | — | — |
| Jun 18, 2026 | Kaye I. Foster-Cheek Director | Option exercise | +2,816 | — | — |
| Jun 18, 2026 | Jacqualyn A. Fouse Director | Option exercise | +2,816 | — | — |
| Jun 18, 2026 | Maykin Ho Director | Option exercise | +2,816 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Agios Pharmaceuticals Inc.
Who is the CEO of Agios Pharmaceuticals Inc.?
Brian Goff is Agios Pharmaceuticals Inc.'s Chief Executive Officer.
How many directors are on Agios Pharmaceuticals Inc.'s board?
Agios Pharmaceuticals Inc.'s board has 12 directors: Brian Goff, Catherine E. Owen, Cynthia Smith, David P. Schenkein, David Scadden, Jacqualyn A. Fouse, Jay T. Backstrom, Jeffrey D. Capello, John Maraganore, Kaye I. Foster-Cheek and 2 others.
Are Agios Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, Agios Pharmaceuticals Inc. insiders made no open-market purchases and sold $4.9 million of shares in 41 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="agios-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.